Table 1.
Clinicopathologic Description of Ri-Paraneoplastic Neurologic Syndrome Breast Cancer (BC) Cohort
| 28 BCs, n (%) | |
| Pathology | |
| Invasive carcinoma NST | 24 (85.7) |
| Lobular carcinoma | 1 (3.6) |
| Papillary carcinoma | 1 (3.6) |
| NA | 2 (7.1) |
| Nottingham gradea | |
| III | 7 (25.0) |
| II | 11 (39.2) |
| I | 1 (3.6) |
| NA | 9 (32.1) |
| Tumor subtype | |
| NA | 6 |
| HER2- hormone receptor + | 18 (81.8) |
| HER2+ hormone receptor + | 3 (13.6) |
| HER2+ hormone receptor - | 0 (0.0) |
| TNBC | 1 (4.5) |
| Receptor expression | |
| NA | 4 |
| ER | 23 (95.8) |
| PR | 13 (54.1) |
| HER2 | 3 (12.5) |
| Tumor size | |
| T0 | 6 (21.4) |
| Tis | 1 (3.6) |
| T1 | 14 (50.0) |
| T2 | 4 (14.2) |
| T3 | 0 (0.0) |
| Lymph node metastasis | |
| N0 | 7 (25.0) |
| N+ | 18 (64.2) |
| NA | 3 (10.7) |
| Tumor-PNS delay | |
| Synchronous | 21 (75.0) |
| Asynchronous | 7 (25.0) |
| Neurologic features | |
| Cerebellar syndrome | 15 (53.6) |
| Extracerebellar features | 13 (46.4) |
| Opsoclonus | 11 |
| Myoclonus | 11 |
| Dystonia | 6 |
| Hypertonia | 12 |
| Oculomotor palsy | 12 |
| Tremor | 5 |
| Limbic encephalitis | 2 |
| mRS score at onset | |
| >2 | 11 |
| <2 | 11 |
| NA | 6 |
| mRS score at last follow-up | |
| >2 | 18 |
| <2 | 8 |
| NA | 2 |
Abbreviations: ER = estrogen receptor; HER2 = cErbB2 protein; mRS = modified Rankin Scale; N+ = cancer cells in at least one lymph node; N0 = no cancer cell in any lymph node; NA = not available; NST = of no special type; PR = progesterone receptor; T0 = no detectable tumor; T1 = tumor is ≤2 cm across; T2 = tumor is >2 cm but ≤5 cm across; T3 = tumor is >5 cm across; Tis = in situ tumor; TNBC = triple-negative breast carcinoma; TNM = tumor node metastasis staging.
Nottingham grade is a composite pathological prognostic score taking into account differentiation, atypia, and mitotic activity ranging from grade I (best prognosis) to III (worse prognosis).